|
Jun
11 2011 Vertex Plans To Provide Access To Potential CF Therapy VX-770 For Patients With Critical Medical NeedOriginally posted in Cystic Fibrosis News From Medical News Today Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA)…
Jun
11 2011 Insmed’s ARIKACEOriginally posted in Cystic Fibrosis News From Medical News Today Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE
|
|
©Uncle & Drunken Crayfish Productions 2011
www.DrunkenCrayfish.com
Visit our NEW site at
PocketBiker.com 
by Raelene
